Peter Thiel-backed psychedelics start-up targets schizophrenia ahead of IPO
Marijuana Stocks, Finance, & InvestingUncategorized January 18, 2021 MJ Shareholders
LONDON — ATAI Life Science, a Peter Thiel-backed start-up, has taken a majority stake in Recognify, a company that is developing drugs to help treat schizophrenia.
Headquartered in Berlin, ATAI is aiming to make psychedelic drugs that can be used to treat mental health disorders. Recognify, meanwhile, is specifically aiming to make a drug that can be used to treat the cognitive impairment associated with schizophrenia, or CIAS.
The latter company was co-founded by German-American biochemist Thomas Sudhof, who was awarded a Nobel laureate in Physiology or Medicine in 2013.
Read More
MJ Shareholders
MJShareholders.com is the largest dedicated financial network and leading corporate communications firm serving the legal cannabis industry. Our network aims to connect public marijuana companies with these focused cannabis audiences across the US and Canada that are critical for growth: Short and long term cannabis investors Active funding sources Mainstream media Business leaders Cannabis consumers
